Michigan is currently home to 2237 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
MitraClip REPAIR MR Study
Recruiting
The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Mitral Valve Regurgitation
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
Recruiting
Liposorber® LA-15 System is a blood purification therapy that selectively removes malignant lipoproteins including low density lipoprotein from circulating blood flow and rapidly reduces the plasma cholesterol level. The system was originally developed for the treatment of patients with serious dyslipidemia such as familial hypercholesterolemia and then applied to improve the dyslipidemia, a common complication of nephrotic syndrome and found to bring about improvement not only with the dyslipid... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
04/29/2025
Locations: Helen DeVos Children's Hospital, Grand Rapids, Michigan
Conditions: Focal Segmental Glomerulosclerosis
Cold Agglutinin Disease Real World Evidence Registry
Recruiting
This is a multinational, multi-center, observational, prospective, longitudinal disease registry designed to collect data on participants with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS). Among them, a minimum of 30 patients with CAD treated with sutimlimab are expected to take part in the sutimlimab cohort study. Patients with CAD who have been enrolled in previous sutimlimab clinical trials (e.g., BIVV009-01/LTS16214 \[NCT02502903,CAD patients\], BIVV009-03/EFC16215 \[NCT03... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Henry Ford Hospital Site Number : 1232, Detroit, Michigan
Conditions: Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS)
CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease
Recruiting
The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/28/2025
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: GVHD,Acute
Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation
Recruiting
The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/28/2025
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Engraftment Syndrome
Study of SGN1 in Patients With Advanced Solid Tumor
Recruiting
Objectives:To assess the safety and tolerability followed by a dose expansion study to characterize safety, and preliminary efficacy of SGN1 in participants with refractory solid tumors. Study Rationale:The mechanism of action for SGN1 is based on the fact that most tumors are methionine dependent. SGN1 is designed to be used as a tumor therapeutic bacterium that can preferentially replicate and accumulate in tumors and starve them of essential amino acids by delivering the oncolytic enzyme L-M... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/28/2025
Locations: Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center, Detroit, Michigan
Conditions: Advanced Solid Tumor
IPT for Major Depression Following Perinatal Loss: Healing After Loss (HeAL)
Recruiting
This study tests the efficacy of interpersonal psychotherapy (IPT) for major depression following perinatal loss (early and late fetal death and early neonatal death) in a sample of 274 women in Flint and Detroit, Michigan. The trial will be the first fully powered randomized trial of treatment for any psychiatric disorder following perinatal loss.
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
04/28/2025
Locations: Anywhere in the entire state of Michigan (treatment is virtual), Flint, Michigan
Conditions: Major Depressive Disorder
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
Recruiting
The aim of this randomized study is to compare the safety and performance of EndoVascular Aneurysm Repair with ESAR using Endurant + Heli-FX™ EndoAnchor™ system and FEVAR using customizable grafts from Cook (Zenith Fenestrated Graft) and Terumo (Fenestrated Anaconda Graft) for the treatment of aortic aneurysms with short aortic neck (4 to 15mm).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Corewell Health (Spectrum), Grand Rapids, Michigan
Conditions: Aortic Aneurysm, Abdominal
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Recruiting
Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Clinical Trial Site, Lansing, Michigan
Conditions: Generalized Myasthenia Gravis
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
Recruiting
The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) describes the second phase of the study that will engage research activities for patients being managed for CHB in usual clinical practice in the US and Canada. The study addresses important clinical q... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Hepatitis B, Hepatitis, Liver Diseases
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
Recruiting
This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: START Midwest, Grand Rapids, Michigan
Conditions: Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma, Ras (Kras or Nras) Gene Mutation, BRAF Gene Mutation, CRAF Gene Mutation, Non-Small Cell Lung Carcinoma, Thyroid Carcinoma, Gliomas, Malignant
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Recruiting
This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + symptom directed therapy (SDT) with placebo + SDT in participants with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by SDT. Parts 1 and 2 will enroll participants with ISM. Participants enrolled in Part 2 will roll over onto Part 3 to receive treatment with elenestinib in an open-label fashion following completion of the earlier... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Michigan Medicine University of Michigan, Ann Arbor, Michigan
Conditions: Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis